- Home
- PD vs SLS Comparison
PD vs SLS Comparison
Compare PD & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | SLS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 924.5M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PD | SLS |
|---|---|---|
| Price | $8.84 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $12.63 | $10.00 |
| AVG Volume (30 Days) | 2.0M | ★ 10.6M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 50.00 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | $110.98 |
| P/E Ratio | $72.23 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $1.39 |
| 52 Week High | $17.45 | $15.88 |
Technical Indicators
Market Signals| Indicator | PD | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 52.26 |
| Support Level | $8.27 | $12.00 |
| Resistance Level | $9.35 | $15.88 |
| Average True Range (ATR) | 0.61 | 1.43 |
| MACD | -0.19 | -0.30 |
| Stochastic Oscillator | 0.40 | 19.42 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.